2.48

1.22% 0.03

Pre-market: 3.15 0.67 +27.02%

Cervomed Inc (CRVO)

Overview News Price History Discussions Forecast Stock Split

Cervomed Inc stock is traded at $2.48, with a volume of 165.06K. It is up +1.22% in the last 24 hours and down -27.91% over the past month. CervoMed Inc is a clinical-stage biotechnology company. It is focused on developing treatments for age-related neurologic disorders. The company's product candidate, Neflamapimod, has the potential to treat and improve synaptic dysfunction, the reversible aspect of the underlying disease processes in DLB and certain other neurological disorders.

Previous Close:

$2.45

Open:

$2.5

24h Volume:

165.06K

Relative Volume:

2.25

Market Cap:

$22.96M

Revenue:

$2.09M

Net Income/Loss:

$-30.04M

P/E Ratio:

-0.7588

EPS:

-3.2685

Net Cash Flow:

$-27.57M

1W Performance:

-14.78%

1M Performance:

-27.91%

6M Performance:

-70.30%

1Y Performance:

-65.17%

1-Day Range:

$2.42

$2.66

1-Week Range:

$2.13

$3.00

52-Week Range:

$2.13

$13.13

Cervomed Inc Stock (CRVO) Company Profile

Name

Cervomed Inc

Sector

Healthcare (1104)

Industry

Biotechnology (621)

Phone

(617) 744-4400

Address

20 PARK PLAZA, BOSTON

Employee

Twitter

Next Earnings Date

2026-05-18

Latest SEC Filings

CRVO's Discussions on Twitter

Compare CRVO vs VRTX, REGN, ARGX, ALNY, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
CRVO Cervomed Inc	2.48	22.96M	2.09M	-30.04M	-27.57M	-3.2685
VRTX Vertex Pharmaceuticals Inc	450.46	114.33B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	614.98	64.47B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	884.20	54.99B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	287.80	38.42B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	160.06	34.03B	742.00K	-1.37B	-1.07B	-7.0731

Cervomed Inc Stock (CRVO) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Dec-18-25	Initiated	Cantor Fitzgerald	Overweight
Mar-13-25	Upgrade	Chardan Capital Markets	Neutral → Buy
Dec-17-24	Downgrade	H.C. Wainwright	Buy → Neutral
Dec-11-24	Downgrade	Chardan Capital Markets	Buy → Neutral
Dec-11-24	Downgrade	Morgan Stanley	Overweight → Underweight
Dec-10-24	Downgrade	D. Boral Capital	Buy → Hold
Dec-06-24	Initiated	ROTH MKM	Buy
Dec-05-24	Initiated	H.C. Wainwright	Buy
Sep-18-24	Initiated	Chardan Capital Markets	Buy
Jul-26-24	Initiated	Morgan Stanley	Overweight
Feb-15-24	Initiated	Canaccord Genuity	Buy
Nov-17-20	Downgrade	H.C. Wainwright	Buy → Neutral
Mar-21-18	Initiated	H.C. Wainwright	Buy

View All

Cervomed Inc Stock (CRVO) Latest News

Jun 15, 2026

CervoMed Inc. Files Form 8-K with SEC – Company Information, Address, and Common Stock Details - Minichart

Jun 15, 2026

Why did CRVO stock crash 22% in pre-market trading today? - MSN

Jun 15, 2026

CervoMed Posts Updated Investor Presentation and Business Overview - TipRanks

Jun 15, 2026

CervoMed director Joshua Boger acquires $2.99m in common stock By Investing.com - Investing.com India

Jun 15, 2026

Cervomed Insider Bought Shares Worth $3,000,000, According to a Recent SEC Filing - marketscreener.com

Jun 15, 2026

CervoMed (CRVO) major holder Boger discloses 19.99% ownership stake - Stock Titan

Jun 15, 2026

Boger family trusts boost CervoMed (CRVO) stake with 955K-unit private deal - Stock Titan

Jun 15, 2026

CervoMed (NASDAQ: CRVO) updates investor presentation for use in meetings - Stock Titan

Jun 15, 2026

CRVO: Advancing neflamapimod to phase III in DLB, with strategic partnership and strong clinical data - TradingView

Jun 15, 2026

Jun 14, 2026

CervoMed to Participate in the H.C. Wainwright 7th Annual Neuro Perspectives Expert Summit - 富途牛牛

Jun 14, 2026

CervoMed Insiders Lose Out As Stock Sinks To US$2.45 - Yahoo Finance

Jun 14, 2026

Jun 12, 2026